Aim: To compare the efficacy of UDCA, Ondansetron and Naltrexone in relieving severe pruritus of cholestasis of AVH. Methods: In a prospective randomized study 75 patients with proven AVH with severe pruritus between Jan 2010 to Jan 2012 were enrolled. Pruritus was measured on Visual Analogue Score (VAS) with severe pruritus defined as VAS > 5. These patients were randomized into three groups (25 in each group) by lottery method. Group A patients have

received Naltrexone 50 mg BD, Group B Ondansetron 4 mg TDS and Group C UDCA 300 mg TDS. All patients were re-assessed on day 5 of treatment by VAS for pruritus. A significant reduction defined as decrease in VAS score by ≥ 3 from baseline. Results: Patients LGK-974 datasheet of Group A (n=25) who received Naltrexone showed significant reduction in pruritus score 22/25 (88%) in comparison to Group B and mTOR inhibitor C patients which showed significant reduction in pruritus in 13/25 (52%) each and the difference was found statistically significant (p =0.009). Mean reduction in VAS score in responders in group A was also higher (4.5) in comparison to group B and C (4.2 and 3.8 respectively).Conclusion:1 .Naltrexone has been found to be most effective

drug to control pruritus of AVH with cholestasis in this study.2.There were no drug related side effects during the short course of treatment or after withdrawal of drug. Disclosures: The following people have nothing to disclose: Ajay K. Jain, Chandrashekhar

Waghmare, SagarJ. Adkar, Shohini Sircar, Mayank Jain, Shreeprakash Jaiswal Cholestasis, the most common and devastating feature of liver diseases, is characterized by an accumulation of toxic bile acids (BAs). N-3 PolyUnsaturated Fatty Acids (n-3 PUFAs) such as 上海皓元医药股份有限公司 the eicosapentaenoic (EPA) and docosahexaenoic acids (DHA) exert protective effects against BA toxicity in liver cells and correct plasma markers of cholestasis in patients with primary sclerosing cholangitis. The present study evaluates how n3 PUFAs impact the plasma BA profile in rodent and humans, and modulate the hepatic, intestinal and renal expression of genes controlling BA homeostasis. Methods: 210 subjects (97 men and 133 women) followed a 6-week supplementation with n-3 PUFAs (1.9g EPA and 1.1g DHA). 28 BAs species were quantified using liquid chromatography coupled to mass spectrometry (LC-MS/MS) in plasma undertaken before and after supplementation. Male mice (n=5/group) were fed for 14 days with an isocaloric control or a DHA-enriched (0.75g/kg/day) diet, and plasma was analyzed for 25 BAs using LC-MS/MS. Human hepatoma (HepG2), colon carcinoma (Caco2) and renal proximal tubule epithelial (RPTEC) cells were treated with EPA and/or DHA, and in the absence or presence of actinomycin D (Act.D: 1μg/μL) or cycloheximide (CHX: 20μg/ml).